| Nov 19 |
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
|
| Nov 12 |
LTRN: Pediatric Rare Cancer in Focus
|
| Nov 9 |
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
|
| Nov 7 |
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
|
| Nov 5 |
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
|
| Oct 31 |
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
|
| Oct 23 |
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
|
| Oct 21 |
Lantern Pharma to Host & Participate in Two Public Webinars During October
|
| Oct 15 |
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
|
